Gilead Sciences (GILD) Benefit/Risk Profile Improves - Oppenheimer

March 19, 2019 9:39 AM EDT Send to a Friend
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $85.00 price target on Gilead Sciences (NASDAQ: GILD) after examining the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login